//fpnotebook.com/
Lorcaserin
Aka: Lorcaserin, Belviq, Belviq XR- See Also
- Medications Associated with Weight Gain
- Orlistat (Xenical)
- Phentermine (Ionamin, Fastin)
- Phentermine and Topiramate (Qsymia, Qnexa)
- Obesity
- Obesity in Children
- Obesity Evaluation
- Obesity Measurement (or Obesity Screening)
- Obesity Risk (or Obesity Comorbid Conditions)
- Obesity Management
- Obesity Medication
- Dietary Supplements in Obesity
- Exercise in Obesity
- Obesity Resources
- Background
- Released in U.S. in 2013
- Removed from market February 2020 in U.S. due to cancer risk
- Efficacy
- Weight loss is 7 pounds more than Placebo in one year
- Weight loss of at least 5% in up to 47% of patients at one year
- Mechanism
- Serotonin 2C (5HT-2C) agonist that increases satiety
- Active at pro-opiomelanocortin (POMC) Neurons of the Hypothalamus
- POMC is cleaved into a-Melanocyte Stimulating Hormone (MSH)
- MSH binds Hypothalamus melanocortin 4 receptors, resulting in decreased food intake
- Thomsen (2008) J Pharmacol Exp Ther 325(2): 577-87 [PubMed]
- Dosing
- Lorcaserin (Belviq) 10 mg orally twice daily
- Belviq XR preparation available for once daily use in 2017
- Stop medication if 5% weight loss is not achieved at 12 weeks
- Adverse Effects
- Cancer Risk
- No associated valvulopathy
- Lorcaserin has 100 fold greater neurologic 5HT-2C affinity over cardiac valve 5HT-2B affinity
- Well tolerated
- More specific, and does not appear to carry same valvular heart disease risks as with fenfluramine
- Constipation
- Cough
- Dry Mouth
- Fatigue
- Nausea
- Hypoglycemia
-
Drug Interactions
- Serotonergic medications (e.g. SSRI, Dextromethorphan)
- Serotonin Syndrome risk
- Serotonergic medications (e.g. SSRI, Dextromethorphan)
- References